Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

HIV-1-infection Clinical Trial

Official title:

A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04027387
• Other study ID #: TMB-365-101
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2019
• Est. completion date: August 18, 2021

Study information

• Verified date: October 2021
• Source: TaiMed Biologics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans. One dose of the study drug is given to each participant, followed by 10 weeks of monitoring for safety and levels of the drug in the blood. The first group of participants will receive the lowest dose (400 mg). If no safety concerns are seen, the next group will begin at a higher dose (800 mg). If no safety concerns are seen in the second group, the third group will begin at the highest dose in this study (1600 mg).

Description:

This phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation study will evaluate the safety, tolerability and pharmacokinetic (PK) parameters of TMB-365 administered via intravenous infusion (IV) to HIV-1 infected participants at one of three successively increasing dose levels: 400 mg, 800 mg, and 1600 mg. Each participant will be monitored for 10 weeks post-administration. All participants will be expected to participate in PK sampling during Weeks 1, 4, 5, and 6.

Beginning with the lowest dosage group, a Data Monitoring Committee (DMC) will review available data after four participants have completed two weeks of post-dose follow-up to determine if dosing of the next dosage group may proceed.

If no dose limiting toxicities (DLTs) emerge, defined as a single Grade 4 or two of the same Grade 3 clinical or laboratory adverse events deemed possibly, probably or definitely related to the study drug, or a serious adverse event deemed possibly, probably or definitely related to the study drug as graded by the DAIDS Table for Grading Severity of Adult and Pediatric Adverse Events Version 2.1, then dosing of the next higher dose group will be permitted.

Dosing in the highest dose group will begin after four of the eight participants in second group have successfully completed the scheduled study drug administration and two weeks of follow-up, and those data, along with all available data from the initial dose group have been reviewed by the DMC and no DLTs or SAEs as defined above are identified.

All participants may initiate standard combination antiretroviral therapy six weeks after receiving the study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 18, 2021
• Est. primary completion date: August 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male or female at least 18 years of age and no greater than 60 years on the day of Screening

• Asymptomatic HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load

• Has not received ART for three months prior to the first dose.

• Screening HIV-1 RNA = 1,000 copies/mL and < 100,000 copies/mL obtained within 60 days prior to the first dose.

• Laboratory values obtained within 60 days prior to the first dose:

• Hemoglobin > 10.0 g/dL

• Platelet count = 100,000/mm3

• Absolute neutrophil count = 1,000/mm3

• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)

• Creatinine clearance (CrCl) of = 50 mL/min

• Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.

• In the opinion of the principal investigator or designee, has understood the information provided; written informed consent needs to be given before any study-related procedures are performed

• Females of childbearing potential, sexually active with a male sex partner, must agree to use one effective method of contraception from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Females of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not postmenopausal (at least one year without menses), and are not otherwise sterile by medical evaluation.

Exclusion Criteria:

• Receipt of TMB-365, TROGARZO (ibalizumab-uiyk), or any anti-CD4 therapeutic (e.g., UB-421) at any time prior to the first dose

• Pregnant, planning a pregnancy during the trial period, or lactating.

• Known allergy/sensitivity or any hypersensitivity to components of the study drug or its formulation, or known allergy to a MAb

• Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt in the previous three years

• Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to the first dose

• Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic corticosteroids), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to the first dose

• Any chronic or acute medical condition, including drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug

• Lack of adequate venous access

• Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens. Note that a change in treatment regimen for intolerance is not considered treatment failure.

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Biological:
• TMB-365
An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

Locations

Country	Name	City	State
Puerto Rico	Clinical Research PR, Inc	San Juan
United States	North Texas Infectious Disease Consultants	Dallas	Texas
United States	Midway Immunology and Research Center	Fort Pierce	Florida
United States	University of Mississippi Medical Center Division of Infectious Diseases	Jackson	Mississippi
United States	Orlando Immunology Center	Orlando	Florida
United States	Quest Clinical Research	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
TaiMed Biologics Inc.	Westat

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of a single 400mg dose of TMB-365	% of subjects with treatment-emergent adverse events	10 weeks
Primary	Safety of a single 800mg dose of TMB-365	% of subjects with treatment-emergent adverse events	10 weeks
Primary	Safety of a single 1600mg dose of TMB-365	% of subjects with treatment-emergent adverse events	10 weeks
Primary	Pharmacokinetics of a single 400mg dose of TMB-365	% CD4 receptor occupancy	4 weeks
Primary	Pharmacokinetics of a single 800mg dose of TMB-365	% CD4 receptor occupancy	4 weeks
Primary	Pharmacokinetics of a single 1600mg dose of TMB-365	% CD4 receptor occupancy	4 weeks
Secondary	Antiviral activity of a single 400 mg dose of TMB-365	Change in log10 plasma HIV-1 RNA	2 weeks
Secondary	Antiviral activity of a single 800 mg dose of TMB-365	Change in log10 plasma HIV-1 RNA	2 weeks
Secondary	Antiviral activity of a single 1600 mg dose of TMB-365	Change in log10 plasma HIV-1 RNA	2 weeks